Although high PDGFR-β expression has been correlated with HCC progression [30], our in vitro studies showed that dovitinib inhibition of PDGFR signaling was not sufficient to inhibit the proliferation of HCC cells. The gene discussed is PDGFRB; the disease is hepatocellular carcinoma.